Nicolaas A Verwey

Summary

Affiliation: VU University Medical Center
Country: The Netherlands

Publications

  1. doi request reprint Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide
    Nicolaas A Verwey
    Department of Neurology and Alzheimer Center, VU University Medical Center, The Netherlands
    Amyloid 20:179-87. 2013
  2. doi request reprint Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements
    Nicolaas A Verwey
    Neurology Department, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands
    Clin Chem Lab Med 46:1300-4. 2008
  3. doi request reprint Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease
    Nicolaas A Verwey
    Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
    Dement Geriatr Cogn Disord 26:522-7. 2008
  4. doi request reprint A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
    N A Verwey
    Department of Clinical Chemistry, VU University Medical Center, HV, The Netherlands
    Ann Clin Biochem 46:235-40. 2009
  5. doi request reprint Quantification of amyloid-beta 40 in cerebrospinal fluid
    Nicolaas A Verwey
    Department of Neurology, VU University Medical Center, Alzheimer Center Amsterdam, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    J Immunol Methods 348:57-66. 2009
  6. doi request reprint Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects
    Nicolaas A Verwey
    Department of Neurology, VU University Medical Center, Alzheimer Center Amsterdam, The Netherlands
    J Alzheimers Dis 20:445-52. 2010
  7. doi request reprint Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease
    Cees Mulder
    Department of Clinical Chemistry, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands
    Clin Chem 56:248-53. 2010
  8. doi request reprint CSF biomarker levels in early and late onset Alzheimer's disease
    Femke H Bouwman
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 30:1895-901. 2009
  9. doi request reprint Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia
    Esther L G E Koedam
    Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
    Alzheimers Dement 9:269-75. 2013
  10. doi request reprint Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 33:1591-8. 2012

Detail Information

Publications13

  1. doi request reprint Immunohistochemical characterization of novel monoclonal antibodies against the N-terminus of amyloid β-peptide
    Nicolaas A Verwey
    Department of Neurology and Alzheimer Center, VU University Medical Center, The Netherlands
    Amyloid 20:179-87. 2013
    ..Omission of FA pre-treatment gives the advantage to allow double IHC stainings, detecting both Aβ and AAF that otherwise would have been structural modificated upon FA pre-treatment...
  2. doi request reprint Variability in longitudinal cerebrospinal fluid tau and phosphorylated tau measurements
    Nicolaas A Verwey
    Neurology Department, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands
    Clin Chem Lab Med 46:1300-4. 2008
    ..The influence of assay variation and duration of storage on changes in cerebrospinal fluid (CSF) levels of tau and phosphorylated (P)-tau with time was evaluated in 112 patients with various neurological disorders...
  3. doi request reprint Serum amyloid p component as a biomarker in mild cognitive impairment and Alzheimer's disease
    Nicolaas A Verwey
    Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
    Dement Geriatr Cogn Disord 26:522-7. 2008
    ..The aim was to investigate if SAP levels in cerebrospinal fluid (CSF) and serum can be used to discriminate controls, AD and mild cognitive impairment (MCI) patients, and to identify incipient AD among MCI patients...
  4. doi request reprint A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease
    N A Verwey
    Department of Clinical Chemistry, VU University Medical Center, HV, The Netherlands
    Ann Clin Biochem 46:235-40. 2009
    ..The aim of this study was to compare the measurements of these CSF biomarkers, between and within centres...
  5. doi request reprint Quantification of amyloid-beta 40 in cerebrospinal fluid
    Nicolaas A Verwey
    Department of Neurology, VU University Medical Center, Alzheimer Center Amsterdam, P O Box 7057, 1007 MB Amsterdam, The Netherlands
    J Immunol Methods 348:57-66. 2009
    ..Reliable methods to detect these biomarkers in CSF are of great importance for understanding the disease mechanisms and for diagnostic purposes...
  6. doi request reprint Additional value of CSF amyloid-beta 40 levels in the differentiation between FTLD and control subjects
    Nicolaas A Verwey
    Department of Neurology, VU University Medical Center, Alzheimer Center Amsterdam, The Netherlands
    J Alzheimers Dis 20:445-52. 2010
    ..Our findings favor the implementation of CSF Abeta40 in differential diagnosis between FTLD, AD, and control subjects...
  7. doi request reprint Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease
    Cees Mulder
    Department of Clinical Chemistry, VU University Medical Center, Alzheimer Center, Amsterdam, The Netherlands
    Clin Chem 56:248-53. 2010
    ..We have used these markers and evaluated their performance...
  8. doi request reprint CSF biomarker levels in early and late onset Alzheimer's disease
    Femke H Bouwman
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 30:1895-901. 2009
    ..To compare CSF levels of beta-amyloid 1-42 (Abeta(1-42)), total tau (tau) and tau phosphorylated at threonine 181 (ptau-181) between AD patients and controls according to age...
  9. doi request reprint Cognitive correlates of cerebrospinal fluid biomarkers in frontotemporal dementia
    Esther L G E Koedam
    Department of Neurology and Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
    Alzheimers Dement 9:269-75. 2013
    ..In this study we investigated the relationships between cerebrospinal fluid (CSF) biomarkers (tau and amyloid-β1-42 [Aβ1-42]) and cognition or behavior in patients with frontotemporal dementia (the behavioral variant, bvFTD)...
  10. doi request reprint Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 33:1591-8. 2012
    ..Contrary to AD-specific markers, nonspecific CSF biomarkers, most notably isoprostane, showed change over time. These markers could potentially be used to monitor disease progression in AD...
  11. doi request reprint Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease
    Jeroen D C Goos
    Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands
    Neurobiol Aging 33:1011.e1-9. 2012
    ..MB distribution related to different amyloid profiles, supporting distinct etiologies. Our results suggest that Aβ42 is retained in cerebrovasculature of AD patients with MBs, while in contrast, VaD patients may possibly drain amyloid...
  12. doi request reprint Relationship of cerebrospinal fluid markers to 11C-PiB and 18F-FDDNP binding
    Nelleke Tolboom
    Departments of Nuclear Medicine and PET Research, VU University Medical Centre, Amsterdam, The Netherlands
    J Nucl Med 50:1464-70. 2009
    ....
  13. doi request reprint Progression from MCI to AD: predictive value of CSF Aβ42 is modified by APOE genotype
    Maartje I Kester
    Alzheimer Center and Department of Neurology, VU University Medical Center Amsterdam, The Netherlands
    Neurobiol Aging 32:1372-8. 2011
    ..To study CSF biomarkers amyloid-beta 1-42 (Aβ42) and total tau (tau) in relation to APOE genotype in their ability to predict progression from mild cognitive impairment (MCI) to Alzheimer's disease (AD)...